Autoimmune polyendocrine syndrome epidemiology and demographics

Revision as of 19:05, 2 October 2017 by Akshun Kalia (talk | contribs)
Jump to navigation Jump to search

Autoimmune polyendocrine syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Autoimmune polyendocrine syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Autoimmune polyendocrine syndrome epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Autoimmune polyendocrine syndrome epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Autoimmune polyendocrine syndrome epidemiology and demographics

CDC on Autoimmune polyendocrine syndrome epidemiology and demographics

Autoimmune polyendocrine syndrome epidemiology and demographics in the news

Blogs on Autoimmune polyendocrine syndrome epidemiology and demographics

Directions to Hospitals Treating Autoimmune polyendocrine syndrome

Risk calculators and risk factors for Autoimmune polyendocrine syndrome epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Epidemiology and Demographics

Incidence

  • The incidence of autoimmune polyendocrine syndrome (APS) type 2 is estimated to be 1-2 per 100,000 individuals worldwide.
  • The most common autoimmune polyendocrine syndrome seen in general population is APS type 2.
  • APS type 1 and type 3 are very rare and extremely rare conditions respectively. Therefore no precise data is available for their incidence.

Prevalence

  • The prevalence of autoimmune polyendocrine syndrome (APS) type 2 is estimated to be 1-4 per 100,000 individuals worldwide.
  • APS type 1 and type 3 are very rare and extremely rare conditions respectively. Therefore no precise data is available for their prevalence.
  • APS type 1 is a very rare disorder and seen mostly in Iran, Sardinia and Finland.
    • The prevalence of APS type is estimated to be 11 cases per 100,000 in Iranian Jews.
    • The prevalence of APS type is estimated to be 7 cases per 100,000 in Sardinians.
    • The prevalence of APS type is estimated to be 4 cases per 100,000 in Finland.

Age

  • Autoimmune polyendocrine syndrome (APS) type 1 commonly affects children in the age group of 3-5 or in 13-15 years of age.
  • Autoimmune polyendocrine syndrome (APS) type 2 commonly affects adults in the third and fourth decade of life.
  • Autoimmune polyendocrine syndrome (APS) type 3 commonly affects 40-60 years old women but may occur in any age group.
  • Most cases of autoimmune polyendocrine syndrome (APS) type 1 and type 2 are symptomatic by early thirties.

Race

  • Autoimmune polyendocrine syndrome (APS) usually affects individuals of the caucasian race.

Gender

  • In autoimmune polyendocrine syndrome type 1, type 2 and type 3 females are more commonly affected than men.

Region

  • The majority of autoimmune polyendocrine syndrome type 1 cases are reported in Finland, Sardinia and Iran. It can be attributed to consanguineous marriages and/or clustering of descendants of common family founders. Other less frequent regions include Norway, Germany, northern Italy and northern Britain.

References

Template:WH Template:WS